NewcelX Ltd., a biotechnology company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, announced the appointment of Dr. Julien Boisdron, MD, to its Scientific Advisory Board. Dr. Boisdron is an experienced diabetes specialist with more than 20 years of global leadership in the field, including senior roles at Swiss-based multinational pharmaceutical companies. He currently serves as Chief Medical Officer, overseeing the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His expertise spans connected-care innovation, advanced insulin management systems, and integrating therapeutic and digital solutions to improve patient outcomes.
Health Technology Insights: EDX Medical to Launch Advanced Bowel Cancer Test in UK
In his new role at NewcelX, Dr. Boisdron will provide strategic guidance for IsletRx, the company’s lead stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes. He will advise on translational strategies, patient adoption, integration with health systems, and global commercialization plans as the program moves toward clinical trials. Dr. Boisdron said he is honored to join the advisory board and looks forward to contributing to next-generation diabetes therapies. He noted that NewcelX’s combined focus on cell therapy and neuroscience innovation offers a strong foundation to advance potentially transformative treatments for patients.
Health Technology Insights: Celltrion Wins CHMP Support for SteQeyma Autoinjector
Prof. Michel Revel, Chief Scientific Officer of NewcelX, commented that Dr. Boisdron’s appointment strengthens the company’s leadership in metabolic and regenerative medicine. He emphasized that Boisdron’s extensive experience in diabetes care and global medical strategy will enhance the company’s guidance as IsletRx progresses. Ronen Twito, Executive Chairman and CEO of NewcelX, highlighted that Type 1 Diabetes remains the core focus of the company’s clinical efforts. He added that Dr. Boisdron’s deep knowledge of diabetes innovation, clinical strategy, and international healthcare systems will be highly valuable in advancing a cell-based therapy designed to meet the needs of insulin-dependent patients.
This strategic appointment reflects NewcelX’s commitment to leveraging world-class expertise in advancing its therapies and strengthening its position in the field of metabolic and regenerative medicine.
Health Technology Insights: Cosan Secures Growth Funding to Expand AI Virtual Care
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
